Actuate Therapeutics Inc
Actuate Therapeutics Inc (ACTU) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · ACTU · as of Sep 30, 2025
Ownership Breakdown
42
Institutional Holders
▲ 4 vs Q2
$80.46M
Total Inst. Value
▲ $11.91M vs Q2
23.93M
Shares Outstanding
freeFloat 35.83%
12.03M
13F Shares Held
▲ 808,930 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
ACTU largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BIOS CAPITAL MANAGEMENT, LP pharmaceutical preparations | 10.05M | 51.15% | 51.15% | $67.23B | Nov 12, 2025 | ▲ 84.9K |
VOSS CAPITAL, LLC pharmaceutical preparations | 896.3K | 4.56% | 4.56% | $6.00B | Nov 20, 2025 | ▲ 610.1K |
VANGUARD GROUP INC pharmaceutical preparations | 316.0K | 1.61% | 1.61% | $2.11B | Nov 7, 2025 | ▲ 51.5K |
BLACKROCK, INC. pharmaceutical preparations | 282.1K | 1.44% | 1.44% | $1.89B | Nov 12, 2025 | ▲ 86.6K |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 145.4K | 74.01% | 74.01% | $972.80M | Nov 12, 2025 | ▲ 27.4K |
NORTHERN TRUST CORP pharmaceutical preparations | 85.5K | 43.50% | 43.50% | $571.69M | Nov 14, 2025 | ▼ 240 |
STATE STREET CORP pharmaceutical preparations | 49.9K | 25.40% | 25.40% | $333.80M | Nov 14, 2025 | ▲ 18.5K |
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO pharmaceutical preparations | 19.3K | 9.82% | 9.82% | $129.12M | Nov 14, 2025 | ▲ 783 |
GLEASON GROUP, INC. pharmaceutical preparations | 19.0K | 9.69% | 9.69% | $127.30M | Oct 16, 2025 | — held |
SFMG, LLC pharmaceutical preparations | 17.0K | 8.65% | 8.65% | $113.73M | Nov 13, 2025 | ▲ 2.5K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
16
Increased
+903.8K shares6
New Positions
first time holders12
Decreased
−86.1K shares2
Sold Out
fully exitedNet shares change (top 50)
+817.7K
+903.8K / −86.1K
Net new holders
+8
6 new / 2 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
ACTU insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
10
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Zabrowski Dan director | May 21, 2026 | Award | 15,000 | $2.42 | $36.3K | 15.0K | Form 4 ↗ |
THOMSON TODD S
| May 21, 2026 | Award | 15,000 | $2.42 | $36.3K | 15.0K | Form 4 ↗ |
Sawhney Roger director | May 21, 2026 | Award | 15,000 | $2.42 | $36.3K | 15.0K | Form 4 ↗ |
RONNEBERG AMY L director | May 21, 2026 | Award | 15,000 | $2.42 | $36.3K | 15.0K | Form 4 ↗ |
Keyes Jason A director | May 21, 2026 | Award | 15,000 | $2.42 | $36.3K | 15.0K | Form 4 ↗ |
Huber Martin H. Jr. director | May 21, 2026 | Award | 15,000 | $2.42 | $36.3K | 15.0K | Form 4 ↗ |
Fletcher Aaron G.L.
| May 21, 2026 | Award | 15,000 | $2.42 | $36.3K | 15.0K | Form 4 ↗ |
SCHMITT DANIEL M President, CEO and Director | Apr 1, 2026 | Award | 237,000 | $2.49 | $590.1K | 237.0K | Form 4 ↗ |
Mazar Andrew Paul Chief Operating Officer | Apr 1, 2026 | Award | 105,000 | $2.49 | $261.5K | 105.0K | Form 4 ↗ |
LYTLE PAUL J Chief Financial Officer | Apr 1, 2026 | Award | 105,000 | $2.49 | $261.5K | 105.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Actuate Therapeutics Inc (ACTU) is primarily owned by institutional investors, who hold approximately 50.3% of total shares outstanding. Company insiders own approximately 64.17%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Actuate Therapeutics Inc is BIOS CAPITAL MANAGEMENT, LP, holding approximately 10.05 million shares — equal to 51.15% of outstanding shares — as of September 30, 2025.
A total of 42 institutional investors currently hold ACTU stock, with a combined institutional value of approximately $80,455,749 as of the most recent 13F filing period.
Frequently asked questions
ACTU ownershipActuate Therapeutics Inc (ACTU) is primarily owned by institutional investors, who hold approximately 50.3% of shares. The largest shareholder is BIOS CAPITAL MANAGEMENT, LP with a 51.15% stake. Company insiders hold 64.17%. Data sourced from SEC Form 13F as of September 30, 2025.